title: Ameliorative potential of montelukast on ischemia-reperfusion injury induced vasculitic neuropathic pain in rat.
abstract: OBJECTIVE
  Ischemia-reperfusion (I/R) event in vascular and nervous system has been documented to rising ischemic and vasculitic neuropathic pain, clinically resembles the complex regional pain syndrome (CRPS). The present study evaluated the effect of montelukast, a cysteinyl leukotriene receptor (Cys-LTC(4) and Cys-LTD(4)) antagonist on ischemia -reperfusion (I/R) induced vasculitic neuropathic pain in rats.
  
  
  METHODS
  Behavioral parameters were assessed at different time intervals (i.e. 0, 1, 7, 14 and 21st day) and biochemical analysis in sciatic nerve tissue samples were also performed along with histopathological studies.
  
  
  RESULTS
  Behavioral pain assessment has shown increase in paw and tail withdrawal threshold in montelukast treated groups against thermal and mechanical stimuli as compared to I/R control group. We observed a decrease in the total calcium, thiobarbituric acid reactive substance (TBARS) and myeloperoxidase (MPO) activity levels, whereas there is rise in reduced glutathione level in montelukast treated groups as compared to I/R control group. However, significant behavioral and biochemical results were observed only in medium and high dose of treated groups which were comparable to normal control group. Moreover, histopathological study has revealed the reduction of I/R induced neuronal edema and axonal degeneration due to montelukast.
  
  
  CONCLUSIONS
  Montelukast has ameliorated I/R induced vasculitic neuropathic pain, these effects may be due to inhibition of lipid peroxidation, reduction of oxidative stress, release of inflammatory mediators and neuroprotective actions. Hence, it could be used as a novel therapeutic agent for the management of vasculitic inflammation related neuropathic pain.
authors.affiliation: Department of Pharmaceutical Sciences & Drug Research, Punjabi University, Patiala-147002, Punjab, India. arunachalammu@gmail.com
authors.forename: Arunachalam
authors.initials: A
authors.lastname: Muthuraman
authors.forename: Muthusamy
authors.initials: M
authors.lastname: Ramesh
authors.forename: Shailja
authors.initials: S
authors.lastname: Sood
mesh_terms: D000085:Acetates / Q000008:administration & dosage / Q000627:therapeutic use*; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D002118:Calcium / Q000378:metabolism; D003521:Cyclopropanes; D005978:Glutathione / Q000378:metabolism; D006358:Hot Temperature; D007101:Immersion; D020024:Leukotriene Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D009437:Neuralgia / Q000150:complications* / Q000473:pathology / Q000523:psychology; D010147:Pain Measurement; D009195:Peroxidase / Q000378:metabolism; D010812:Physical Stimulation; D011804:Quinolines / Q000008:administration & dosage / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D011930:Reaction Time / Q000187:drug effects / Q000502:physiology; D015427:Reperfusion Injury / Q000188:drug therapy* / Q000209:etiology* / Q000523:psychology; D012584:Sciatic Nerve / Q000378:metabolism; D013440:Sulfides; D017392:Thiobarbituric Acid Reactive Substances / Q000378:metabolism; D014657:Vasculitis / Q000150:complications* / Q000473:pathology / Q000523:psychology
chemical_list: D000085:Acetates; D003521:Cyclopropanes; D020024:Leukotriene Antagonists; D011804:Quinolines; D013440:Sulfides; D017392:Thiobarbituric Acid Reactive Substances; D009195:Peroxidase; D005978:Glutathione; C093875:montelukast; D002118:Calcium